Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results

Tuesday, January 6, 2026 1 min read

Key Takeaway: Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results